In this issue:
Biomarkers of venetoclax response in RRMM
CARTITUDE-1: CAR-T cell therapy for B-cell maturation antigen
Carfilzomib, dexamethasone and daratumumab for RRMM
Newly diagnosed patients with functional high-risk myeloma
Daratumumab-based regimen in newly diagnosed MM
Quantitative immunoprecipitation mass spectrometry in smoldering MM
B-cell maturation antigen T cell engager for RRMM
Anti-CD38 monoclonal antibody for RRMM
Selinexor in penta-exposed triple-class refractory myeloma with plasmacytoma
Sequential CD19- and BCMAspecific chimeric antigen receptor T cell treatment for RRMM
Please login below to download this issue (PDF)